OverviewSuggest Edit

Horizon Therapeutics is a biopharmaceutical company building a pipeline and exploring potential uses for medicines. It offers medicines to treat rare, inflammation, and rheumatic diseases. In addition, the company provides patient advocacy, disease education as well as patient support and savings programs.

TypePublic
Founded2008
HQBallsbridge, IE
Websitehorizontherapeutics.com
Employee Ratings3.4

Latest Updates

Employees (est.) (Dec 2019)1,200(+20%)
Job Openings161
Revenue (FY, 2019)$1.3 B(+8%)
Share Price (Sept 2020)$78.3 (+4%)
Cybersecurity ratingAMore

Key People/Management at Horizon Therapeutics

Timothy Walbert

Timothy Walbert

Chairman, President and Chief Executive Officer
Tina Ventura

Tina Ventura

Senior Vice President, Investor Relations
Brian K. Beeler

Brian K. Beeler

Executive Vice President, General Counsel
Ruth Venning

Ruth Venning

Executive Director, Investor Relations
Geoffrey M. Curtis

Geoffrey M. Curtis

Executive Vice President, Corporate Affairs and Chief Communications Officer
Paul W. Hoelscher

Paul W. Hoelscher

Executive Vice President, Chief Financial Officer
Show more

Horizon Therapeutics Office Locations

Horizon Therapeutics has offices in Ballsbridge, Chicago, Lake Forest, Novato and in 3 other locations
Ballsbridge, IE (HQ)
Connaught House Burlington Rd
Mannheim, DE
13 Joseph-Meyer-Straße
Chicago, US
10 S Wacker Dr #2550
Lake Forest, US
Landmark of Lake Forest 2, 150 S Saunders Rd
Novato, US
3 Hamilton Landing #260Novato
South San Francisco, US
1828, One, Tower Pl
Show all (7)

Horizon Therapeutics Financials and Metrics

Horizon Therapeutics Revenue

Embed Graph
View revenue for all periods
Horizon Therapeutics's revenue was reported to be $1.30 b in FY, 2019
USD

Revenue (Q1, 2020)

355.9m

Gross profit (Q1, 2020)

258.5m

Gross profit margin (Q1, 2020), %

72.6%

Net income (Q1, 2020)

(13.6m)

EBIT (Q1, 2020)

(16.5m)

Market capitalization (25-Sept-2020)

18.0b

Closing stock price (25-Sept-2020)

78.3

Cash (31-Mar-2020)

754.6m

EV

17.6b
Horizon Therapeutics's current market capitalization is $18 b.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

6.9m19.6m74.0m297.0m757.0m981.1m1.1b1.2b1.3b

Revenue growth, %

301%155%30%

Cost of goods sold

7.3m12.7m14.6m76.8m219.5m393.3m546.3m422.3m362.2m

Gross profit

(340.0k)7.0m59.4m220.2m537.5m587.8m510.0m785.3m937.9m
USDQ2, 2011

Financial Leverage

1.9 x
Show all financial metrics

Horizon Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

91/100

SecurityScorecard logo

Horizon Therapeutics Online and Social Media Presence

Embed Graph

Horizon Therapeutics News and Updates

Should you invest in Zoom Video, Microsoft, Roku, Horizon Therapeutics, or Workhorse Group?

NEW YORK, Sept. 23, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ZM, MSFT, ROKU, HZNP, and WKHS. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different...

Thinking about buying stock in Sorrento Therapeutics, Aerpio Pharmaceuticals, Horizon Therapeutics, Riot Blockchain, or Royal Caribbean Cruises?

NEW YORK, Aug. 5, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for SRNE, ARPO, HZNP, RIOT, and RCL. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Horizon Therapeutics halted for FDA advisory committee meeting on treatment for thyroid eye disease

Horizon Therapeutics Plc shares were halted in premarket trade Friday, ahead of a U.S. Food and Drug Administration advisory committee meeting to discuss a treatment for Thyroid Eye Disease, a serious autoimmune disorder. The FDA's Dermatologic and Ophthalmic Drugs Advisory Committee will meet at …

UPDATE: Horizon Pharma stock soars 17% premarket on positive trial of eye disease treatment

Horizon Pharma plc shares soared 17% in premarket trade Thursday, after the company announced positive results in a late-stage trial of a treatment for active thyroid eye disease, or TED. The company said the phase 3 trial of teprotumumab met its primary endpoint of improving proptosis, or bulging …

Horizon Therapeutics Blogs

Horizon Therapeutics plc Appoints Dr. Sue Mahony to Board of Directors

Horizon Therapeutics plc Appoints Dr. Sue Mahony to Board of Directors Content Import Thu, 08/01/2019 - 08:00 Horizon Therapeutics plc Appoints Dr. Sue Mahony to Board of Directors 08/01/19 This release is a backfill from a News Wire General …

Horizon Therapeutics plc Wins International CSR Excellence Award for Partnership with Perspectives Math and Science Academy

Horizon Therapeutics plc Wins International CSR Excellence Award for Partnership with Perspectives Math and Science Academy Content Import Thu, 07/25/2019 - 08:00 Horizon Therapeutics plc Wins International CSR Excellence Award for Partnership with Perspectives Math and Science Academy …

Horizon Therapeutics plc Announces U.S. FDA Acceptance of its New Drug Application to Make PROCYSBI® (Cysteamine Bitartrate) Available as Oral Granules in Packets

Horizon Therapeutics plc Announces U.S. FDA Acceptance of its New Drug Application to Make PROCYSBI® (Cysteamine Bitartrate) Available as Oral Granules in Packets Content Import Thu, 07/18/2019 - 09:00 Horizon Therapeutics plc Announces U.S. FDA Acceptance of its New Drug Application to Ma…

Horizon Therapeutics plc to Release Second-Quarter 2019 Financial Results and Host Webcast on Aug. 7, 2019

Horizon Therapeutics plc to Release Second-Quarter 2019 Financial Results and Host Webcast on Aug. 7, 2019 Content Import Tue, 07/16/2019 - 08:01 Horizon Therapeutics plc to Release Second-Quarter 2019 Financial Results and Host Webcast on Aug. 7, 2019 07/16/19 …

Horizon Therapeutics plc Announces Pricing of Private Offering of Senior Notes

Horizon Therapeutics plc Announces Pricing of Private Offering of Senior Notes Content Import Thu, 07/11/2019 - 16:45 Horizon Therapeutics plc Announces Pricing of Private Offering of Senior Notes 07/11/19 This release is a backfill from a News Wire …

Horizon Therapeutics plc Announces Proposed Private Offering of Senior Notes

DUBLIN --(BUSINESS WIRE)--Jul. 10, 2019-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced that Horizon Pharma USA, Inc. , its wholly-owned subsidiary, intends, subject to market and other considerations, to offer $500 million aggregate principal amount of senior notes due 2027.
Show more

Horizon Therapeutics Frequently Asked Questions

  • When was Horizon Therapeutics founded?

    Horizon Therapeutics was founded in 2008.

  • Who are Horizon Therapeutics key executives?

    Horizon Therapeutics's key executives are Timothy Walbert, Tina Ventura and Brian K. Beeler.

  • How many employees does Horizon Therapeutics have?

    Horizon Therapeutics has 1,200 employees.

  • What is Horizon Therapeutics revenue?

    Latest Horizon Therapeutics annual revenue is $1.3 b.

  • What is Horizon Therapeutics revenue per employee?

    Latest Horizon Therapeutics revenue per employee is $1.1 m.

  • Who are Horizon Therapeutics competitors?

    Competitors of Horizon Therapeutics include Opiant Pharmaceuticals, Mylan and Esperion Therapeutics.

  • Where is Horizon Therapeutics headquarters?

    Horizon Therapeutics headquarters is located at Connaught House Burlington Rd, Ballsbridge.

  • Where are Horizon Therapeutics offices?

    Horizon Therapeutics has offices in Ballsbridge, Chicago, Lake Forest, Novato and in 3 other locations.

  • How many offices does Horizon Therapeutics have?

    Horizon Therapeutics has 7 offices.